Glaxis Capital Management’s Celgene Corp CELG Stock Holding History

Glaxis Capital Management’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-6,000	Closed	-$569K	–	35
2014 Q3	$569K	Buy	+6,000	New	+$541K	2.6%	9
2013 Q3	–	Sell	-26,000	Closed	-$1.52M	–	70
2013 Q2	$1.52M	Buy	+26,000	New	+$1.56M	3.58%	12

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Glaxis Capital Management's CELG Position: Q4 2014 in Review

Glaxis Capital Management sold out of Celgene Corp (CELG) in Q4 2014, closing a stake of 6,000 shares — an estimated $569K sold.

Glaxis Capital Management first reported a position in CELG in Q2 2013 and held it in 2 quarters. The position peaked at $1.52M in Q2 2013. 1,161 funds tracked by Wall St. Rank hold CELG as of Q4 2014.

Glaxis Capital Management reported no remaining Celgene Corp position as of Q4 2014 after selling out during the quarter.
Glaxis Capital Management sold 6,000 Celgene Corp shares in Q4 2014, an estimated $569K.
Glaxis Capital Management first reported a position in Celgene Corp in Q2 2013 and held it in 2 quarters.
Glaxis Capital Management's Celgene Corp position peaked at $1.52M in Q2 2013.
1,161 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2014.

Based on Glaxis Capital Management's 13F filing for Q4 2014, filed 11 Feb 2015.